APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 3mg capsule bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

rivastigmine hydrogen tartrate, Quantity: 4.8 mg

Available from:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

rivastigmine hydrogen tartrate

Pharmaceutical form:

Capsule

Composition:

Excipient Ingredients: titanium dioxide; microcrystalline cellulose; Gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Administration route:

Oral

Units in package:

56, 500, 100

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Product summary:

Visual Identification: Hard gelatine calsule with orange, opaque body and orange opaque cap. Imprinted "APO R3" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2010-07-27